HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.
6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Psychopharmacology
Psychopharmacology
It is the branch of science that deals with the study of the effects of the drugs or medications which affect the mind and behavior and are used to treat mental disorders. This firequiresuire continuous study in order to understand all the clinically relevant principles of pharmacokinetic (the hat body does with the medications) and pharmacodynamics (what drugs do to the body). These pharmacodynamic and pharmacokinetic studies of the drug include the major parameters like protein binding, half-life, Polymorphic genes, and drug-to-drug interaction.
Committee Members
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain GAB 2025 Speakers
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Malasri Chaudhery Malgeri
Recovery com, United States
Jana Furstova
Palacký University Olomouc, Czech RepublicSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States